logo
  

Ipsen Announces FDA Priority Review For Palovarotene NDA In Patients With Rare Genetic Disorder

The U.S. Food and Drug Administration has accepted for Priority Review Ipsen's (IPSEY) resubmitted New Drug Application or NDA for investigational palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva or FOP, an ultra-rare genetic disorder.

Ipsen is seeking approval of palovarotene, an oral, selective retinoic-acid receptor gamma (RAR?) agonist for the prevention of heterotopic ossification.

The FDA has assigned 29 December 2022 as the Prescription Drug User Fee Act goal date, which is on track with anticipated regulatory submission timelines.

Palovarotene is an oral investigational, selective retinoic-acid receptor gamma (RAR?) agonist being developed as a potential treatment for people living with the debilitating ultra-rare genetic disorder fibrodysplasia ossificans progressiva.

Palovarotene, which received rare pediatric disease and Breakthrough Therapy Designations from the U.S. Food and Drug Administration for the potential treatment of FOP, was acquired by Ipsen through the acquisition of Clementia Pharmaceuticals in April 2019.

The palovarotene New Drug Application was initially accepted by the FDA for Priority Review on May 28, 2021, and Ipsen announced withdrawal of the NDA on August 13, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ford Motor Co. is seeking a new trial in a Georgia court after a jury reached a $1.7 billion verdict in a lawsuit against the automotive major regarding a truck rollover accident, The Wall Street Journal reported. In the new court filings, Ford said it was unfairly precluded from providing evidence and thus defending against claims that its trucks were defective. Omnichannel retailer Macy's, Inc. announced Monday plans to hire colleagues for more than 41,000 full- and part-time seasonal positions for the upcoming holiday season. The colleagues will be positioned at its Macy's, Bloomingdale's and Bluemercury stores, supply chain locations and call centers. Seffner, Florida -based Canyon Furniture Co. is recalling ladders sold with bunk bed and hutch sets citing entrapment and strangulation risks, the U.S. Consumer Product Safety Commission said. The about 2,100 units of Canyon Lake and Cottage Colors Bunk Bed and Hutch Sets were sold exclusively at Rooms To Go.
Follow RTT